MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+
Gespeichert in:
| Veröffentlicht in: | Revista Portuguesa de Pneumología |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Sociedade Portuguesa de Pneumologia
2016
|
| Schlagworte: | |
| Online-Zugang: | https://www.redalyc.org/articulo.oa?id=169747617008 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|